Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER AF-PCI: Rivaroxaban strategies in AF patients after PCI
NCT01830543Phase 3Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- May 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by Janssen Scientific Affairs. Started May 2013; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01830543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830543.